Previous Article | Next Article 
Infection and Immunity, December 1998, p. 5636-5642, Vol. 66, No. 12
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Activity of the Mitogenic Pasteurella
multocida Toxin Requires an Essential C-Terminal Residue
Philip N.
Ward,1
Antony J.
Miles,1
Ian G.
Sumner,2
Lewis H.
Thomas,1 and
Alistair
J.
Lax3,*
Institute for Animal Health, Compton
Laboratory, Compton, Newbury, Berkshire, RG20
7NN,1
Institute of Food Research,
Reading, Berkshire, RG6 2EF,2 and
Oral
Microbiology, Guy's, King's and St. Thomas' Dental Institute,
Guy's Hospital, London, SE1 9RT,3 United
Kingdom
Received 11 June 1998/Returned for modification 24 July
1998/Accepted 17 September 1998
 |
ABSTRACT |
Pasteurella multocida toxin (PMT) is a potent mitogen
that also affects bone resorption. PMT acts intracellularly and is
therefore postulated to have several domains involved in different
aspects of its function. The toxin contains eight cysteine residues.
Mutants with individual substitutions for each of these residues were constructed, and the effects of these on the biological activity of the
toxin were determined by cultured-cell assays. Only the most C-terminal
of the eight cysteines (C1165) was essential for full activity,
although mutation of the cysteine residue at position 1159 caused a
slight but reproducible loss of potency. In animal challenge
experiments, mutant toxin (C1165S) was not toxic to piglets, even at
doses exceeding a lethal dose of active PMT 1,000-fold. The mutant and
wild-type toxins displayed identical purification characteristics,
similar susceptibility to proteolytic digestion, and circular dichroism
profiles, which indicated that no gross structural changes had taken
place. The function of the essential C1165 residue is not yet known,
although its most likely role is an enzymatic one at or near the
catalytic center of the toxin.
 |
INTRODUCTION |
Pasteurella multocida
toxin (PMT) is a highly potent mitogen which at picomolar
concentrations induces DNA synthesis leading to cell division in
cultured and primary cells. The toxin affects several signal
transduction pathways, resulting in increased inositol phosphate
production, stimulation of protein kinase C activity, Ca2+
mobilization, and actin rearrangements (17, 20, 33, 38, 39).
PMT action stimulates bone resorption (13, 19, 40) by
mitogenic activation of osteoblasts, leading to their growth and dedifferentiation (15, 28); these osteoblasts induce bone breakdown by osteoclasts (29). Experimental nasal infection of animals can also produce proliferation of bladder
epithelium (18). This is of potential importance for
human health, since toxigenic P. multocida has been isolated
from some farm workers (9).
There is convincing evidence that PMT is internalized and processed via
a low-pH compartment prior to modifying an intracellular target, which
has yet to be identified. The earliest cellular events following
exposure to PMT take several hours to arise, compared to the rapid
response triggered by membrane-acting growth factors. Similarly, early,
but not late, addition of lysosomotrophic agents or neutralizing
antibody to PMT-treated cells inhibits DNA synthesis (33).
PMT has no action on permeabilized Swiss 3T3 cells, which suggests that
processing via the correct trafficking route might be required to
release activated toxin or a fragment to the cytosol. Furthermore, PMT
is highly resistant to proteolysis at a neutral pH but becomes
susceptible at a pH of 5 or lower (36).
PMT is a large molecule (146 kDa). By analogy with other
intracellularly acting toxins, it would be predicted to comprise individual domains for binding, internalization, and catalytic activity
(26). There is little structural information, and individual domains have not been identified. An N-terminal region homologous to
the cytotoxic necrotizing factors (CNF) from Escherichia
coli (11, 30) is predicted to have a hydrophobic
helical structure and thus is likely to be a transmembrane domain
(24, 37). The C terminus of CNF has been shown to be
catalytic, while a cell binding domain is located in the N terminus
(25).
Many large toxins use disulfide bonds to link or stabilize
multiple-domain structures and to enable the delivery of the catalytic fragment to the correct intracellular environment (6).
The catalytic domains of diphtheria toxin (4), cholera
toxin (14), ricin (3), pertussis toxin
(27), Pseudomonas aeruginosa exotoxin A
(2), and tetanus toxin (1) are all stabilized in
this way. Reduction of the disulfide bond either releases
active fragments or enables processing or conformational changes to
take place. Moreover, the absence of disulfide bonds within the
diphtheria toxin A fragment is crucial for translocation, which can be
blocked by the inclusion of disulfide bridges by genetic
modification (12). PMT has 8 cysteine residues,
but their significance is not known. We have evaluated the role of
each cysteine residue, using site-directed mutagenesis. An
inactive mutant of PMT was identified, and a structural and
biological analysis of this mutant is reported.
 |
MATERIALS AND METHODS |
Materials.
All chemical reagents used were of the
highest grade available and were obtained from BDH Merck, unless
stated otherwise. Microbiological media were prepared from Difco
Laboratories products. Cell culture media and materials were from
Flow Laboratories. Antibiotics, ethidium bromide, agarose, and
acrylamide-bisacrylamide (premixed) were purchased from Sigma Ltd.
N,N,N',N'-tetramethylethylenediamine (TEMED) was purchased from Bio-Rad Laboratories. Restriction enzymes and DNA-modifying enzymes were purchased from Boehringer Mannheim, Promega Corporation, or New England Biolabs and used according to the
manufacturer's instructions. Oligonucleotides were synthesized in
house on an Applied Biosystems 392 DNA/RNA synthesizer by Karen Mawditt. Radioisotopes were purchased from DuPont-New England Nuclear.
Phenol was obtained from Rathburn Chemicals. DEAE Sephacel ion-exchange
resin and Octyl Sepharose 4 Fast Flow medium were purchased from Pharmacia.
Bacterial strains, bacteriophage, plasmids, and growth
conditions.
Full-length recombinant toxin is expressed from its
own promoter in E. coli hosts at considerably higher levels
than that observed in P. multocida, and for this reason all
manipulations using infectious material were carried out under category
3+ regulations as defined by the United Kingdom Advisory
Committee for Genetic Manipulation.
Two E. coli K-12 strains were used as hosts for recombinant
PMT constructs: XL1-Blue (Stratagene) as a general purpose host and
CJ236 (Dut
Ung
) (Boehringer Mannheim) for
the incorporation of uracil in plasmid DNA. Bacteriophages VCS M13 and
R408 (Stratagene) were employed as "helper phages" in the rescue of
the single-stranded DNA mutagenesis template from CJ236. A
ClaI fragment (of approximately 4 kb) containing the
upstream and coding sequences of PMT was excised from the clone pAJL12
(23) and used to make a highly expressing construct, pTox2,
in phagemid pBluescript II SK(
) (Stratagene).
E. coli strains were grown routinely, in Luria-Bertani broth
(35) or solid medium, aerobically at 37°C. Enriched
culture medium (2× yeast extract tryptone medium) was used during the generation of the mutagenesis template to obtain maximal bacterial growth rates. Antibiotic supplements to growth media were used as
follows. Tetracycline was used at 10 µg/ml as a means to select for
XL1-Blue containing the F' episome, which enabled the formation of pili
and subsequent superinfection by helper phage. Similarly, chloramphenicol was used at 15 µg/ml to select for the F' episome in
CJ236 cultures. All recombinant clones of PMT were grown in the
presence of 50 µg of ampicillin/ml.
DNA isolation.
Plasmid DNA for use in subcloning and
sequencing reactions was isolated by alkaline lysis (35).
Single-stranded DNA was prepared from CJ236 transformed with pTox2, by
using either the VCS M13 or the R408 helper bacteriophage (Stratagene),
according to the manufacturer's instructions.
Site-directed mutagenesis.
Negative-strand single-stranded
DNA was prepared and used as a mutagenesis template under the
conditions specified in the pBluescript II Exo/Mung DNA sequencing
system protocol supplied by Stratagene. Oligonucleotides of 26 bases
were made to span cysteine codons. Each oligonucleotide was made
degenerate at the first and second positions corresponding to the
cysteine codons. The oligonucleotides were complementary to the
antisense strand of pTox2. All mutant clones were subjected to DNA
sequence analysis around the region of the induced mutation by using
the Sequenase version 2.0 system (U.S. Biochemical Corp.) in accordance
with the manufacturer's instructions.
Polyacrylamide gel electrophoresis (PAGE).
Proteins were
separated in denatured and reduced from on 4% stacking and 8%
resolving gels (22). Native protein gels were run under
similar conditions but without denaturing or reducing agents.
Silver staining.
Following acrylamide gel electrophoresis,
proteins were visualized by a silver-staining technique described by
Heukeshoven and Dernick (16).
Toxin purification.
Cleared crude cell lysates and toxin
purified for the Swiss 3T3 cell assay were prepared as described
previously (41). The preparation of sufficient purified
toxin for circular dichroism (CD) analysis and the pig toxicity study
required a different approach. Initial fractionation of a cleared
bacterial cell lysate by anion-exchange chromatography was carried out
as described previously. Selected fractions were dialyzed overnight
against 500 mM ammonium sulfate-25 mM sodium phosphate (pH 6.5) at
room temperature and were further fractionated by hydrophobic
interaction chromatography on Octyl Sepharose 4 Fast Flow medium by
using a stepped ammonium sulfate gradient from 500 to 0 mM in 25 mM sodium phosphate (pH 6.5). Selected fractions were concentrated by
using 30K Microsep microconcentrators (Filtron Technology Corp., Northborough, Mass.) according to the manufacturer's instructions.
EBL cell cytotoxicity assay.
The cytotoxicity of toxin
preparations was assessed by serial dilution on standard 96-well
microtiter plates by a previously published method
(34), with the following modifications. Ten-microliter amounts of cleared crude cell lysate were serially diluted 10-fold with
90 µl of Eagle's minimum essential medium (Flow Laboratories) containing 10% fetal calf serum, and 90 µl of a suspension of embryonic bovine lung (EBL) cells at 3 × 105/ml was
added to each well. After incubation for 2 days at 37°C under a 5%
CO2 atmosphere, the cells were stained with 0.1% crystal violet in 1% acetic acid-neutral buffered formalin for 1 h and were examined microscopically to determine dilution endpoints for
cytotoxicity. A minimum of three independent endpoint determinations were conducted for each cysteine mutant.
Swiss 3T3 fibroblast DNA synthesis assay.
Incorporation of
[3H]thymidine into DNA was assessed by the method of
Dicker and Rozengurt (8). Confluent, quiescent cultures of
Swiss 3T3 cells were washed and incubated at 37°C under a 5% CO2 atmosphere in 2 ml of Dulbecco's modified Eagle's
medium-Waymouth medium in a 1:1 (vol/vol) ratio, containing 0.037 MBq
(1 µCi) of [3H]thymidine per ml and various
concentrations of wild-type or mutant PMT in triplicate. After 40 h, DNA synthesis was assessed by measuring the level of
[3H]thymidine incorporated into the acid-precipitable
material. The average of three values for each sample was determined.
Pig toxicity experiment.
A litter of gnotobiotic piglets was
split into five groups of two. At 2 weeks of age, the piglets were
weighed and injected intraperitoneally with 2 ml of phosphate buffer
containing toxin preparations as follows: group A, phosphate buffer
control; group B, 400 ng of wild-type PMT/kg of body weight; group C,
40 µg of mutant PMT (C1165S)/kg; groups D and E, 500 µg of mutant
PMT (C1165S)/kg. Following injection, the pigs were observed at regular
intervals and their temperatures were recorded on a daily basis for 5 days. Animals in group B showed clinical signs of a toxic reaction and were killed for humane reasons 2 days after inoculation. The remaining piglets were all killed healthy 2 weeks after inoculation. At postmortem examination, the left and right nasal turbinate bones of
each piglet were removed and weighed. Liver, kidney, ureter, bladder,
and nasal turbinate samples from all piglets were fixed in neutral
buffered formalin, embedded in paraffin wax, sectioned, and stained for
microscopic examination by hematoxylin and eosin and by Alcian
blue-periodic acid-Schiff stain.
Proteolysis of PMT.
Wild-type and mutant toxins were
incubated with endoproteinase Glu-C (EC 3.4.21.19) (Sigma) at a 1:1
molar ratio in 25 mM phosphate (pH 6.5) or 50 mM
NH4CH3CO2 for 1 h at 37°C.
The reaction was stopped, neutralized, and visualized as described by
Smyth et al. (36). Some digestions were carried out in the
presence of a range of sodium dodecyl sulfate (SDS) concentrations or
at different pHs.
Spectral analysis.
CD spectra were measured with a
Jobin-Yvon CD6 spectropolarimeter at 22°C. The instrument, maintained
under a constant nitrogen purge, was calibrated with an aqueous
solution of d-10-camphosulfonic acid. Far-UV (180 to 260 nm)
spectra were obtained from protein dissolved in 25 mM phosphate buffer
(pH 6.5) at 1 mg/ml by using a 0.01-cm-pathlength sealed silica cell.
Results shown are averages of three scans; the signal averaging time
for each scan at each wavelength was 3 s. Data are expressed as mean
residue ellipticities, [
]M, derived from
the molecular ellipticities, [
], measured in millidegrees, by
using the equation [
]M = ([
] × 100)/(C × d × N), where C is the
molar protein concentration, d is the pathlength in
centimeters, and N is the number of peptide bonds. Spectral
deconvolution and secondary-structure analysis was accomplished by
using the CONTIN analysis program of Provencher and Glockner
(32).
 |
RESULTS |
Construction of cysteine mutants.
Oligonucleotides to mutate
each of the eight cysteine residues were degenerate at the first and
second positions of the cysteine codons in order to substitute a range
of amino acids. The frequency of mutation was sufficiently high to
enable candidate clones to be screened directly by sequence analysis.
Twenty-six mutant clones were isolated and are listed in Table 1. A
minimum of two different amino acid substitutions were found at all
positions except C1159. Two of the clones contained deletions that
resulted in frameshift mutations that encoded premature stop codons.
Biological properties of mutant PMT.
Cleared crude lysates of
each mutant clone, with the exception of the two frameshift mutant
clones, produced a protein of a molecular weight corresponding to that
of PMT (Table 1), and this enabled rough
comparisons of the amounts of toxin expressed by each clone to be made.
The cytopathic effect of these samples on EBL cells was compared to
that caused by wild-type toxin (Fig. 1).
Point mutation of any of the first seven cysteine residues of PMT did
not appreciably alter the cytopathic effect of the toxin on EBL cells.
However, all four clones with mutations at the eighth cysteine residue
(C1165) had either a dramatically reduced cytopathic effect or no
cytopathic effect on EBL cells. These four independently derived
mutants contained substitutions of glycine, serine, or arginine.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Cytotoxicity of PMT cysteine mutants for EBL cells.
Cleared crude cell lysates of mutant clones were prepared from cultures
grown to stationary phase (41). Tenfold serial dilutions of
each lysate were made in microtiter plates with cell culture medium,
and equal volumes of a suspension of EBL cells at 3 × 105/ml were added to each well. After incubation for 2 days, the cells were stained and examined microscopically to determine
dilution endpoints for cytotoxicity, which was compared to that of
wild-type (WT) PMT. A minimum of three independent endpoint
determinations were conducted for each cysteine mutant. Amino acid
substitutions are designated according to the single-letter code. The
locations of mutations in the full-length toxin are indicated on the
line below.
|
|
Toxin was purified from representative mutant clones encoding
C26G1, C113G1, C230G, C257S, C793G,
C905D1, C1159G1, and C1165G1. The
purification characteristics of toxin from all these clones were
unaltered during anion-exchange chromatography and on preparative gels.
Toxin concentrations were standardized by comparison by eye of the
staining intensities of purified mutant toxins on SDS-PAGE gels with
that of a preparation of wild-type toxin of known concentration.
The mitogenicity of the purified mutant toxins for Swiss 3T3
cells was determined by using [3H]thymidine
incorporation. The correlation between the mitogenic activity of
wild-type toxin and those of mutants C26G1,
C113G1, C230G, and C257S (data not shown) and mutants
C793G and C905D1 (Fig. 2) was
very close, while the C1159G1 mutant induced maximal DNA
synthesis only at concentrations approximately 10-fold higher than
those of wild-type toxin. Repetition using toxin repurified from the
same clone (C1159G1) and from a different clone encoding the same mutation (C1159G2) gave similar results (data not
shown). Mutant toxin encoding C1165G1 was not
mitogenic at a concentration in excess of 100 ng/ml, i.e.,
at least 2 orders of magnitude greater than that required to
achieve half-maximal stimulation by wild-type toxin (Fig. 2).
Subsequent experiments showed that toxin purified from mutant C1165S
also was not mitogenic (data not shown). These effects were all highly
reproducible.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Stimulation of DNA synthesis by purified mutant and
wild-type PMT in Swiss 3T3 cells. The abilities of mutant toxin
preparations to stimulate incorporation of [3H]thymidine
into the DNA of quiesced Swiss 3T3 fibroblasts were measured over a
concentration range of 0.05 to 120 ng/ml and compared to that of
wild-type PMT. Each result is expressed as a percentage of the level of
[3H]thymidine incorporation stimulated by 10% fetal
calf serum (fcs) (446 × 103 cpm ± 2.13%).
Measurements were made in triplicate in two independent
experiments, one of which is shown for the four cysteine residues
located in the C terminus. Standard errors were calculated at the
maximum level of stimulation to be ±3.57% for wild-type PMT, 3.96%
for C1159G, and 3.77% for C1165G.
|
|
The toxicity of the C1165S mutant was also assessed in a whole-animal
model, in order to examine the possibility that the C1165 mutants might
have retained some biological activity that could not be identified by
cultured-cell assays. The C1165S mutant was chosen because serine
is the amino acid most biochemically similar to cysteine. Gnotobiotic
piglets given an intraperitoneal dose of 400 ng of wild-type
toxin per kg of body weight developed a toxic reaction, fluctuating
temperatures, clinical signs of apathy, and anorexia over the 2 days
following injection and had to be killed. Postmortem examination
revealed pallor, congestion and slight jaundice of the liver, and
thickening of bladder walls. Microscopic examination of the liver
revealed congestion, foci of active Kupffer cells in one piglet, and
vacuolation and moderate cloudy swelling of hepatocytes in both
piglets. Hyperplasia of the epithelium of the renal pelvis was evident.
Marked vacuolation and hyperplasia of the epithelia of both ureters and
the bladder were observed (Fig. 3). There
was no effect on turbinate bone growth, the overlying respiratory
epithelium, or the tubular epithelium of the kidney. Control piglets
and piglets dosed with 40 or 500 µg of the purified C1165S mutant
toxin/kg appeared healthy for 2 weeks following injection. No
differences or abnormalities were recognized macroscopically in these
piglets or in the five tissues examined microscopically upon postmortem
examination at 2 weeks. There was no significant difference between the
weights of the turbinate bones from piglets treated with mutant toxin
and those from controls.

View larger version (152K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of purified C1165S mutant toxin in a gnotobiotic
pig model. A bladder (A) and a ureter (C) from a piglet dosed
intraperitoneally with 400 ng of wild-type toxin/kg show marked
epithelial hyperplasia compared with the normal stratified epithelia of
a bladder (B) and a ureter (D) from a piglet treated with 1,250 times
the equivalent dose of purified C1165S mutant toxin. Bar, 100 µm.
|
|
Biophysical properties of mutant PMT.
The CD profiles of
wild-type PMT and the C1165G mutant were identical (Fig.
4), indicating that replacement of C1165
did not grossly affect structure. The possibility of more subtle
changes that might not be distinguished by CD analysis was examined by comparison of the protease sensitivity of PMT under various conditions. At a neutral pH, mutant PMT (C1165S) was highly resistant to
endoproteinase Glu-C, even at a 1:1 molar ratio of enzyme to substrate,
although there was limited cleavage of a small proportion of the mutant protein that was not observed with wild-type toxin. Both wild-type and
mutant toxins became highly susceptible to endoproteinase Glu-C at pH 5 (Fig. 5). Similarly, the
mutant toxin appeared slightly more susceptible to proteolysis than
wild-type toxin at the lowest SDS concentrations and became highly
susceptible to proteolysis at a slightly lower concentration of
denaturant than was required for wild-type toxin (Fig. 5).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 4.
CD spectra of wild-type PMT (A) and C1165G mutant PMT
(B). Wild-type and mutant PMT were prepared as described in the text at
1 mg/ml in 25 mM phosphate buffer, pH 6.5, and far-UV (180 to 260 nm)
spectra were obtained. The CD spectra shown were derived from three
scans of each sample.
|
|

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 5.
Susceptibility of wild-type and mutant PMT to
proteolysis. (A and B) Wild-type PMT (A) and the C1165S mutant (B)
incubated with endoproteinase Glu-C (glu-c) over a range of pH
conditions. Lanes 1, pH 4.5; lanes 2, pH 5.0; lanes 3, pH 5.3; lanes 4, pH 6.7; lanes 5, pH 8.0; lanes 6, pH 6.7 plus 0.1% SDS; lanes 7, toxin
alone; lanes 8, endoproteinase Glu-C alone. (C and D) Wild-type PMT (C)
and the C1165S mutant (D) incubated with endoproteinase Glu-C over a
range of SDS concentrations at pH 6.5. Lanes 1, no SDS; lanes 2, 0.005% SDS; lanes 3, 0.0075% SDS; lanes 4, 0.010% SDS; lanes 5, 0.0125% SDS; lanes 6, 0.015% SDS; lanes 7, 0.020% SDS; lanes 8, toxin alone; lanes 9, endoproteinase Glu-C alone. Silver-stained
SDS-PAGE gels of the reaction products are shown.
|
|
 |
DISCUSSION |
We have shown that of the eight cysteine residues in PMT, only the
most C-terminal residue is essential for its biological activity.
Replacement of C1165 with any of three different amino acids completely
abolished all cytotoxicity or mitogenicity for cultured cells. In
addition, there were no toxic or proliferative changes in piglets given
a dose 1,000 times in excess of a lethal dose of wild-type toxin.
Furthermore, we have shown that the mutant toxin appeared to be
correctly folded as judged by CD measurements. The transition to
protease sensitivity at low pHs mirrored that found in wild-type toxin
(36), although there was some limited proteolytic cleavage
at a neutral pH. The mutant was also more susceptible to protease
digestion in the presence of mild denaturants. Taken together, this
indicates that the amino acid substitution has not affected gross
structure, but the slight increase in proteolytic susceptibility
suggests that the mutant toxin can adopt a more dynamic structure and
is susceptible to proteolysis. The loss of biological activity in only
one of these mutants showed that, unlike many other toxins, there were
no essential disulfide bonds in PMT. Furthermore, since PMT is
monomeric (42), C1165 cannot be postulated to form an
interchain disulfide bond.
There are several possible roles for this crucial cysteine
residue. Given that it is highly unlikely to form an essential disulfide bond, it could be involved in membrane interactions or play a
role in the postulated catalytic mode of action of PMT. Several lines
of evidence suggest that the latter is its most likely function.
First, the region of highest homology to CNF is strongly
predicted to be the translocation domain. In all intracellularly acting
toxins in which structural assignments have been made, the receptor
binding domain is contiguous with the transmembrane domain. Indeed, the
correlation between the CNF and PMT sequences is poorest in the
C-terminal region that contains the catalytic domain of CNF, which is
known to have a target and a mode of action different from those of PMT
(7, 21, 33). Injection of oocytes with PMT preincubated with
antibodies against an N-terminal peptide reduced the mitogenic response
(43). This could be due to blocking of catalytic activity or
might reflect interference with toxin processing, or even steric
hindrance by the attachment of the large antibody molecule. Although
little is known about the domain architecture of PMT, recent detailed
structural analysis using secondary-structure prediction algorithms and
based on homology to proteins of known structure has given strong
indications of the likely domain structure of PMT and would support our
postulated role for the C terminus in catalysis (37). The
C-terminal part of PMT is predicted to comprise an alternating
alpha/beta structure, which is commonly found in the catalytic domain
of proteins.
Cysteine can also contribute to catalysis through the formation of
metal ion complexes like those in bacterial ferredoxins or zinc finger
motifs (5). Petersen (31) suggested the location of a metal binding domain towards the C terminus of PMT, and copper ions have been reported to decrease the toxicity of PMT
(10). However, despite a local abundance of histidine and
methionine residues in proximity to C1159 and C1165, the C-terminal
region of PMT does not encode classical metal binding motifs, and the molecular role of this essential residue has yet to be determined.
 |
ACKNOWLEDGMENTS |
We acknowledge the contribution of J. H. Morgan and B. Charleston to the animal experiments. In addition, we thank the staff of the gnotobiotic unit and of the histology and photography departments.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Oral
Microbiology, Guy's, King's and St. Thomas' Dental Institute, Floor
28, Guy's Hospital, London, SE1 9RT, United Kingdom. Phone: 44 (0) 171 955 2848. Fax: 44 (0) 171 955 2847. E-mail:
a.lax{at}umds.ac.uk.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Ahnert-Hilger, G.,
M. F. Bader,
S. Bhakdi, and M. Gratzl.
1989.
Introduction of macromolecules into bovine adrenal-medullary chromaffin cells and rat pheochromacytoma cells (PC12) by permeabilization with Streptolysin-O inhibitory effect of tetanus toxin on catecholamine secretion.
J. Neurochem.
52:1751-1758[Medline].
|
| 2.
|
Allured, V. S.,
R. J. Collier,
S. F. Carroll, and D. B. McKay.
1986.
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0Å resolution.
Proc. Natl. Acad. Sci. USA
83:1320-1324[Abstract/Free Full Text].
|
| 3.
|
Barbieri, L.,
M. G. Battelli, and F. Stirpe.
1982.
Reduction of ricin and other plant toxins by thiol:protein disulphide oxidoreductases.
Arch. Biochem. Biophys.
216:380-383[Medline].
|
| 4.
|
Collier, R. J., and J. Kandel.
1971.
Structure and activity of diphtheria toxin.
J. Biol. Chem.
246:1496-1503[Abstract/Free Full Text].
|
| 5.
|
Creighton, T. E.
1993.
Proteins: structures and molecular properties, 2nd ed.
W. H. Freeman and Co., New York, N.Y.
|
| 6.
|
de Paiva, A.,
B. Poulain,
G. W. Lawrence,
C. C. Shone,
L. Tauc, and J. O. Dolly.
1993.
A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly.
J. Biol. Chem.
268:20838-20844[Abstract/Free Full Text].
|
| 7.
|
de Rycke, J.,
P. Mazars,
J.-P. Nougayrede,
C. Tasca,
M. Boury,
F. Herault,
A. Valette, and E. Oswald.
1996.
Mitotic block and delayed lethality in HeLa epithelial cells exposed to Escherichia coli BM2-1 producing cytotoxic necrotizing factor type 1.
Infect. Immun.
64:1694-1705[Abstract].
|
| 8.
|
Dicker, P., and E. Rozengurt.
1980.
Phorbol esters and vasopressin stimulate DNA synthesis by a common mechanism.
Nature
287:607-612[Medline].
|
| 9.
|
Donnio, P. Y.,
J. L. Avril,
P. M. Andre, and J. Vaucel.
1991.
Dermonecrotic toxin production by strains of Pasteurella multocida isolated from man.
J. Med. Microbiol.
34:333-337[Abstract].
|
| 10.
|
Erler, W.,
B. Jacob, and J. Schlegel.
1994.
The influence of cations on the lethality and on the formation of the toxin of Pasteurella multocida.
Microbiol. Res.
149:89-93[Medline].
|
| 11.
|
Falbo, V.,
T. Pace,
L. Picci,
E. Pizzi, and A. Caprioli.
1993.
Isolation and nucleotide sequence of the gene encoding cytotoxic necrotizing factor 1 of Escherichia coli.
Infect. Immun.
61:4909-4914[Abstract/Free Full Text].
|
| 12.
|
Falnes, P. Ø.,
S. Choe,
I. H. Madshus,
B. Wilson, and S. Olsnes.
1994.
Inhibition of membrane translocation of diphtheria toxin A-fragment by internal disulfide bridges.
J. Biol. Chem.
269:8402-8407[Abstract/Free Full Text].
|
| 13.
|
Felix, R.,
H. Fleisch, and P. L. Frandsen.
1992.
Effect of Pasteurella multocida toxin on bone resorption in vitro.
Infect. Immun.
60:4984-4988[Abstract/Free Full Text].
|
| 14.
|
Gill, D. M.
1977.
Mechanism of action of cholera toxin.
Adv. Cyclic Nucleotide Res.
8:85-118[Medline].
|
| 15.
|
Gwaltney, S. M.,
R. J. S. Galvin,
K. B. Register,
R. B. Rimler, and M. R. Ackermann.
1997.
Effects of Pasteurella multocida toxin on porcine bone marrow cell differentiation into osteoclasts and osteoblasts.
Vet. Pathol.
34:421-430[Abstract].
|
| 16.
|
Heukeshoven, J., and R. Dernick.
1985.
Simplified method for silver staining of proteins in polyacrylamide gels and the mechanism of silver staining.
Electrophoresis
6:103-112.
|
| 17.
|
Higgins, T. E.,
A. C. Murphy,
J. M. Staddon,
A. J. Lax, and E. Rozengurt.
1992.
Pasteurella multocida toxin is a potent inducer of anchorage-independent cell growth.
Proc. Natl. Acad. Sci. USA
89:4240-4244[Abstract/Free Full Text].
|
| 18.
|
Hoskins, I. C.,
L. H. Thomas, and A. J. Lax.
1997.
Nasal infection with Pasteurella multocida causes proliferation of bladder epithelium in gnotobiotic pigs.
Vet. Rec.
140:22[Free Full Text].
|
| 19.
|
Kimman, T. G.,
C. W. G. M. Lowik,
L. J. A. van de Wee-Pals,
C. W. Thesingh,
P. Defize,
E. M. Kamp, and O. L. M. Bijvoet.
1987.
Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida.
Infect. Immun.
55:2110-2116[Abstract/Free Full Text].
|
| 20.
|
Lacerda, H. M.,
A. J. Lax, and E. Rozengurt.
1996.
Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation and focal contact assembly in Swiss 3T3 cells.
J. Biol. Chem.
271:439-445[Abstract/Free Full Text].
|
| 21.
|
Lacerda, H. M.,
G. D. Pullinger,
A. J. Lax, and E. Rozengurt.
1997.
Cytotoxic necrotizing factor 1 from Escherichia coli and dermonecrotic toxin from Bordetella bronchiseptica induce p21rho-dependent tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 cells.
J. Biol. Chem.
272:9587-9596[Abstract/Free Full Text].
|
| 22.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 23.
|
Lax, A. J., and N. Chanter.
1990.
Cloning of the toxin gene from Pasteurella multocida and its role in atrophic rhinitis.
J. Gen. Microbiol.
136:81-87[Medline].
|
| 24.
|
Lax, A. J.,
N. Chanter,
G. D. Pullinger,
T. H. Higgins, and E. Rozengurt.
1990.
Sequence analysis of the potent mitogenic toxin of Pasteurella multocida.
FEBS Lett.
277:59-64[Medline].
|
| 25.
|
Lemichez, E.,
G. Flatau,
M. Bruzzone,
P. Boquet, and M. Gauthier.
1997.
Molecular localization of the Escherichia coli cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains.
Mol. Microbiol.
24:1061-1070[Medline].
|
| 26.
|
Moss, J., and M. Vaughan.
1990.
ADP-ribosylating toxins and G proteins: insights into signal transduction.
American Society for Microbiology, Washington, D.C.
|
| 27.
|
Moss, J.,
S. J. Stanley,
D. L. Burns,
J. A. Hsia,
D. A. Yost,
G. A. Myers, and E. L. Hewlett.
1983.
Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet activating protein).
J. Biol. Chem.
258:11879-11882[Abstract/Free Full Text].
|
| 28.
|
Mullan, P. B., and A. J. Lax.
1996.
Pasteurella multocida toxin is a mitogen for bone cells in primary culture.
Infect. Immun.
64:959-965[Abstract].
|
| 29.
|
Mullan, P. B., and A. J. Lax.
1998.
Pasteurella multocida toxin stimulates bone resorption by osteoclasts via interaction with osteoblasts.
Calcif. Tissue Int.
63:340-345[Medline].
|
| 30.
|
Oswald, E.,
M. Sugai,
A. Labigne,
H. C. Wu,
C. Fiorentini,
P. Boquet, and A. D. O'Brien.
1994.
Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers.
Proc. Natl. Acad. Sci. USA
91:3814-3818[Abstract/Free Full Text].
|
| 31.
|
Petersen, S. K.
1990.
The complete nucleotide sequence of the Pasteurella multocida toxin gene and evidence for a transcriptional repressor, TxaR.
Mol. Microbiol.
4:821-830[Medline].
|
| 32.
|
Provencher, S. W., and J. Glockner.
1981.
Estimation of globular protein secondary structure from circular dichroism.
Biochemistry
20:33-37[Medline].
|
| 33.
|
Rozengurt, E.,
T. E. Higgins,
N. Chanter,
A. J. Lax, and J. M. Staddon.
1990.
Pasteurella multocida toxin: potent mitogen for cultured fibroblasts.
Proc. Natl. Acad. Sci. USA
87:123-127[Abstract/Free Full Text].
|
| 34.
|
Rutter, J. M., and P. D. Luther.
1984.
Cell culture assay for toxigenic Pasteurella multocida.
Vet. Rec.
114:393-396[Abstract].
|
| 35.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd Ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 36.
|
Smyth, M. G.,
R. W. Pickersgill, and A. J. Lax.
1995.
The potent mitogen Pasteurella multocida toxin is highly resistant to proteolysis but becomes susceptible at lysosomal pH.
FEBS Lett.
360:62-66[Medline].
|
| 37.
| Sowdhamini, R., P. N. Ward, and A. J. Lax. Unpublished data.
|
| 38.
|
Staddon, J. M.,
C. J. Barker,
A. C. Murphy,
N. Chanter,
A. J. Lax,
R. H. Michell, and E. Rozengurt.
1991.
Pasteurella multocida toxin, a potent mitogen, increases inositol 1,4,5-triphosphate and mobilises Ca2+ in Swiss 3T3 cells.
J. Biol. Chem.
266:4840-4847[Abstract/Free Full Text].
|
| 39.
|
Staddon, J. M.,
N. Chanter,
A. J. Lax,
T. E. Higgins, and E. Rozengurt.
1990.
Pasteurella multocida toxin, a potent mitogen, stimulates protein kinase C-dependent and -independent protein phosphorylation in Swiss 3T3 cells.
J. Biol. Chem.
265:11841-11848[Abstract/Free Full Text].
|
| 40.
|
Sterner-Kock, A.,
B. Lanske,
S. Überschär, and M. J. Atkinson.
1995.
Effects of Pasteurella multocida toxin on osteoblastic cells in vitro.
Vet. Pathol.
32:274-279[Abstract].
|
| 41.
|
Ward, P. N.,
T. E. Higgins,
A. C. Murphy,
P. B. Mullan,
E. Rozengurt, and A. J. Lax.
1994.
Mutation of a putative ADP-ribosylation motif in the Pasteurella multocida toxin does not affect mitogenicity.
FEBS Lett.
342:81-84[Medline].
|
| 42.
| Ward, P. N., M. G. Smyth, A. G. Rowe, and
A. J. Lax. Unpublished data.
|
| 43.
|
Wilson, B. A.,
X. Zhu,
M. Ho, and L. Lu.
1997.
Pasteurella multocida toxin activates the inositol triphosphate signaling pathway in Xenopus oocytes via Gq -coupled phospholipase c- 1.
J. Biol. Chem.
272:1268-1275[Abstract/Free Full Text].
|
Infection and Immunity, December 1998, p. 5636-5642, Vol. 66, No. 12
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Orth, J. H. C., Fester, I., Preuss, I., Agnoletto, L., Wilson, B. A., Aktories, K.
(2008). Activation of G{alpha}i and Subsequent Uncoupling of Receptor-G{alpha}i Signaling by Pasteurella multocida Toxin. J. Biol. Chem.
283: 23288-23294
[Abstract]
[Full Text]
-
Aminova, L. R., Luo, S., Bannai, Y., Ho, M., Wilson, B. A.
(2008). The C3 domain of Pasteurella multocida toxin is the minimal domain responsible for activation of Gq-dependent calcium and mitogenic signaling. Protein Sci.
17: 945-949
[Abstract]
[Full Text]
-
Kitadokoro, K., Kamitani, S., Miyazawa, M., Hanajima-Ozawa, M., Fukui, A., Miyake, M., Horiguchi, Y.
(2007). Crystal structures reveal a thiol protease-like catalytic triad in the C-terminal region of Pasteurella multocida toxin. Proc. Natl. Acad. Sci. USA
104: 5139-5144
[Abstract]
[Full Text]
-
Orth, J. H. C., Aktories, K., Kubatzky, K. F.
(2007). Modulation of Host Cell Gene Expression through Activation of STAT Transcription Factors by Pasteurella multocida Toxin. J. Biol. Chem.
282: 3050-3057
[Abstract]
[Full Text]
-
Blocker, D., Berod, L., Fluhr, J. W., Orth, J., Idzko, M., Aktories, K., Norgauer, J.
(2006). Pasteurella multocida toxin (PMT) activates RhoGTPases, induces actin polymerization and inhibits migration of human dendritic cells, but does not influence macropinocytosis. Int Immunol
18: 459-464
[Abstract]
[Full Text]
-
Orth, J. H. C., Lang, S., Aktories, K.
(2004). Action of Pasteurella multocida Toxin Depends on the Helical Domain of G{alpha}q. J. Biol. Chem.
279: 34150-34155
[Abstract]
[Full Text]
-
Baldwin, M. R., Pullinger, G. D., Lax, A. J.
(2003). Pasteurella multocida Toxin Facilitates Inositol Phosphate Formation by Bombesin through Tyrosine Phosphorylation of G{alpha}q. J. Biol. Chem.
278: 32719-32725
[Abstract]
[Full Text]
-
Pullinger, G. D., Sowdhamini, R., Lax, A. J.
(2001). Localization of Functional Domains of the Mitogenic Toxin of Pasteurella multocida. Infect. Immun.
69: 7839-7850
[Abstract]
[Full Text]
-
Thomas, W., Pullinger, G. D., Lax, A. J., Rozengurt, E.
(2001). Escherichia coli Cytotoxic Necrotizing Factor and Pasteurella multocida Toxin Induce Focal Adhesion Kinase Autophosphorylation and Src Association. Infect. Immun.
69: 5931-5935
[Abstract]
[Full Text]
-
Busch, C., Orth, J., Djouder, N., Aktories, K.
(2001). Biological Activity of a C-Terminal Fragment of Pasteurella multocida Toxin. Infect. Immun.
69: 3628-3634
[Abstract]
[Full Text]
-
Meysick, K. C., Mills, M., O'Brien, A. D.
(2001). Epitope Mapping of Monoclonal Antibodies Capable of Neutralizing Cytotoxic Necrotizing Factor Type 1 of Uropathogenic Escherichia coli. Infect. Immun.
69: 2066-2074
[Abstract]
[Full Text]
-
Seo, B., Choy, E. W., Maudsley, S., Miller, W. E., Wilson, B. A., Luttrell, L. M.
(2000). Pasteurella multocida Toxin Stimulates Mitogen-activated Protein Kinase via Gq/11-dependent Transactivation of the Epidermal Growth Factor Receptor. J. Biol. Chem.
275: 2239-2245
[Abstract]
[Full Text]